The synergistic effect of humanized monoclonal antibodies targeting insulin-like growth factor 1 receptor (IGF-1R) and chemotherapy

• Published in: Current drug targets Vol. 15; no. 7; p. 674
• Main Authors: Sui, Ping, Cao, Hongxin, Meng, Long, Hu, Pingping, Ma, Honghai, Du, Jiajun
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2014
• Subjects: Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cell Line, Tumor; Cell Survival - drug effects; Clinical Trials as Topic; Drug Synergism; Humans; Hypoglycemia - chemically induced; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Receptor, IGF Type 1 - antagonists & inhibitors; Xenograft Model Antitumor Assays

IGF-1R, an important member of the IGF signaling system, is a plasma-membrane-bound receptor composed of two α-subunits and two β-subunits. IGF-1R has been revealed to play a pivotal role in cancer cell proliferation, differentiation, apoptosis and phenotype transformation, resulting uncontrolled tu...